8th Nov 2011 15:39
Proteome Sciences plc
Directors dealings
8th November 2011 Proteome Sciences plc ("Proteome") is pleased to announce that on 7 November it granted options under its 2011 Long Term Incentive Plan to certain directors. The details of the option grants are set out below:
Name | Title | Exercise price | Number of options | Total number of options held post grant | % of issued share capital |
Christopher Pearce | Chief Executive Officer | 1p | 1,174,269 | 1,451,343 | 0.75 |
Ian Pike | Chief Operating Officer | 1p | 654,971 | 902,141 | 0.47 |
James Malthouse | Finance Director | 1p | 767,251 | 1,025,559 | 0.53 |
For further information please contact:
Proteome Sciences plc | |
www.proteomics.com | Tel: +44 (0)1932 865065 |
Christopher Pearce, Chief Executive Officer | |
James Malthouse, Finance Director | |
Dr. Ian Pike, Chief Operating Officer | |
Nominated Adviser | |
Singer Capital Markets Limited | Tel: +44 (0)20 3205 7500 |
Shaun Dobson/Claes Spång | |
Public Relations | |
FTI Consulting | IKON Associates |
Ben Atwell/Mo Noonan | Adrian Shaw |
Tel: +44 (0)20 7269 7116 | Tel: +44 (0)1483 271291 |
Email: [email protected] | Mobile: +44 (0)7979 900733 |
Email: [email protected] |
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.
Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.
Visit: http://www.proteomics.com.
Related Shares:
Proteome